Limits...
Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.

Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N - BMJ Open (2014)

Bottom Line: We found no evidence of differences between ranibizumab, aflibercept, bevacizumab and triamcinolone for improving vision.The antivascular endothelial growth factors (VEGFs) are likely to be favoured because they are not associated with steroid-induced cataract formation.Not registered.

View Article: PubMed Central - PubMed

Affiliation: Department of Population Health and Primary Care, University of East Anglia, Norwich, UK.

No MeSH data available.


Related in: MedlinePlus

Rankogram for gaining ≥3 lines—distribution of the probabilities of every treatment being ranked at each of the possible six positions.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120318&req=5

BMJOPEN2014005292F4: Rankogram for gaining ≥3 lines—distribution of the probabilities of every treatment being ranked at each of the possible six positions.

Mentions: Figure 3 displays a forest plot of the risk ratio and 95% CrI in proportions of patients gaining ≥3 lines for all the possible pairwise comparisons. In terms of proportions of patients gaining ≥3 lines, triamcinolone 4 mg, ranibizumab 0.5 mg, bevacizumab 1.25 mg and aflibercept 2 mg had a higher probability of being more effective than a sham and dexamethasone (figure 4). There was no difference in the proportions of patients gaining ≥3 lines between triamcinolone 4 mg, ranibizumab 0.5 mg, bevacizumab 1.25 mg and aflibercept 2mg.


Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.

Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N - BMJ Open (2014)

Rankogram for gaining ≥3 lines—distribution of the probabilities of every treatment being ranked at each of the possible six positions.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120318&req=5

BMJOPEN2014005292F4: Rankogram for gaining ≥3 lines—distribution of the probabilities of every treatment being ranked at each of the possible six positions.
Mentions: Figure 3 displays a forest plot of the risk ratio and 95% CrI in proportions of patients gaining ≥3 lines for all the possible pairwise comparisons. In terms of proportions of patients gaining ≥3 lines, triamcinolone 4 mg, ranibizumab 0.5 mg, bevacizumab 1.25 mg and aflibercept 2 mg had a higher probability of being more effective than a sham and dexamethasone (figure 4). There was no difference in the proportions of patients gaining ≥3 lines between triamcinolone 4 mg, ranibizumab 0.5 mg, bevacizumab 1.25 mg and aflibercept 2mg.

Bottom Line: We found no evidence of differences between ranibizumab, aflibercept, bevacizumab and triamcinolone for improving vision.The antivascular endothelial growth factors (VEGFs) are likely to be favoured because they are not associated with steroid-induced cataract formation.Not registered.

View Article: PubMed Central - PubMed

Affiliation: Department of Population Health and Primary Care, University of East Anglia, Norwich, UK.

No MeSH data available.


Related in: MedlinePlus